SecBot SecBot
SECBOTREPLAY Home › Report › SCLX

SCLX · Scilex's indirect subsidiary, ACEA Therapeutics, has agreed to sell…

Scilex Holding Company · PRESS-RELEASE filed May 5, 2026 at 13:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 5, 2026 at 13:00 ET

Scilex's indirect subsidiary, ACEA Therapeutics, has agreed to sell ACEA Pharma to Phoenix Asia Holdings in exchange for 100M newly-issued Phoenix shares valued at $1B. Upon closing, Scilex's subsidiary will own ~82% of the combined company, which will be renamed ACEA Pharma and list on Nasdaq. This transformative deal could significantly increase the value of Scilex's assets, but is subject to regulatory and stock exchange approvals.

  • Deal value: $1,000,000,000 (100,000,000 shares at $10.00/share)
  • ACEA Thera (Scilex subsidiary) to receive 100M shares of Phoenix, representing ~82% of the combined entity
  • Phoenix to be renamed ACEA Pharma, Inc. and list on Nasdaq
  • Expected closing by end of Q2 2026, subject to regulatory and Nasdaq approval

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access